Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Phase II Study - Trial of a Phototherapy Light Device to Improve Sleep Health (PHOTONS)

1. November 2021 aktualisiert von: MICHAEL A GRANDNER, University of Arizona
There are few devices currently on the market claiming to improve sleep. This study will investigate the efficacy of phototherapy on improving sleep, in the form of a wearable neck device used at night.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This study will investigate the efficacy of phototherapy on improving sleep, in the form of a wearable neck device used at night. Phototherapy has been shown to improve chronic pain, cerebral blood flow, neurological function, and capillary growth in skeletal muscle. A device worn at night may improve sleep onset, total sleep time, or modify sleep architecture. Improved cardiovascular function may facilitate a decrease in core body temperature needed for sleep onset. Relaxation from direct heat may help to decrease cortisol levels, thus reducing the number of night-time arousals. It may also decrease circulating levels of norepinephrine (NE), one of the main neurotransmitters involved in arousal. The aim of this study is to evaluate if the device worn leads to greater next-day wellbeing and cognitive function as a result of increased slow-wave activity.

Studientyp

Interventionell

Einschreibung (Voraussichtlich)

30

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

30 Jahre bis 60 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Between the ages of 18 and 60 years old
  2. Able to read and write fluently in English
  3. Access to a mobile device for video calls, online questionnaires, syncing devices, and communication with study staff
  4. Access to a residential mailing address for shipping study materials
  5. Exhibit a score of >8 on the Insomnia Severity Index
  6. Self-report that they have a problem with their sleep that they wish to improve

Exclusion Criteria:

  1. Have a moderate to severe current sleep disorder
  2. Have a current psychiatric disorder
  3. Are taking medication that would interfere with sleep, including beta blockers, antidepressants, antianxiety medications, hypnotics, or stimulants
  4. Have a medical condition that would interfere with their ability to complete all study procedures or would render measurements invalid (e.g., some autoimmune conditions, cardiac conditions, endocrine conditions, or chronic pain conditions)
  5. Exhibit a regular sleep schedule, where bed and wake times are kept within a 2-hour window 7 days per week
  6. Exhibit a regular sleep schedule during the night, beginning no earlier than 9pm and ending no later than 10am
  7. Have not engaged in shift work for the past month, and will refrain from shift work during the study
  8. Are unable to restrict alcohol consumption to no more than 2 drinks within 4 hours of sleep
  9. Are unable to restrict caffeine use to no coffee or caffeinated beverages after 12pm during the study
  10. Regularly smoke or use other tobacco products
  11. Regularly use cannabis-derived medicinal products
  12. Are pregnant
  13. Are a full-time caregiver to an individual that requires attending during the evening and night

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Active
An active phototherapy device
Gerät: Phototherapy device
The active phototherapy device will emit light
Schein-Komparator: Sham (Placebo)
An inactive device
Gerät: Phototherapy device
The active phototherapy device will emit light

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in subjective rating of the device across a 3-week intervention
Zeitfenster: Change in subjective rating of the device from baseline (pre; Day 0) to after 21 days of wearing it (post)
There will be a subjective rating of the phototherapy device using a series of questions assessing device's effect on sleep and next-day function at the end of the trial.
Change in subjective rating of the device from baseline (pre; Day 0) to after 21 days of wearing it (post)
Change in Insomnia Severity Index (ISI) scores across a 3-week intervention
Zeitfenster: Change from baseline over the course of the study (after 21 days of wearing the device)
The ISI is a 7-item insomnia screening tool that is the gold standard for quantifying severity of clinical insomnia symptoms.
Change from baseline over the course of the study (after 21 days of wearing the device)
Change in objective sleep efficiency across a 3-week intervention
Zeitfenster: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
Objective sleep efficiency will be measured with a wearable device (Oura ring) that is worn for the duration of the study and captures sleep and wake data using actigraphy.
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in mean sleep latency assessed using sleep diaries
Zeitfenster: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
Sleep latency, or time taken to fall asleep, will be assessed using morning sleep diaries completed by the participant upon awakening. The mean sleep latency during the baseline period (pre) will be compared to after three weeks of wearing the phototherapy device (post).
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
Change in Karolinska Sleepiness Scale (KSS) score
Zeitfenster: Change from before intervention (pre) to post three weeks of wearing the phototherapy device (Day 21)..
The Karolinska Sleepiness Scale (KSS) measures situational sleepiness on a 9-point scale
Change from before intervention (pre) to post three weeks of wearing the phototherapy device (Day 21)..
Circadian Energy Scale (CIRENS) score
Zeitfenster: Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
CIRENS is a very short and simple chronotype measurement tool based on energy. The CIRENS consists of two introspective questions about the usual energy level (very low, low, moderate, high, or very high, scored 1 to 5) in the morning and in the evening. The difference between energy level scores (-4 to 4) felt by respondents in the evening and morning defines the chronotype score and classification.
Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
Positive and Negative Affect Scales (PANAS) Positive Affect
Zeitfenster: Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
The Positive and Negative Affect Scales are brief screening measures that assess both positive and negative emotional experiences. This scale will allow for separate assessment of impact on positive mood.
Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
Positive and Negative Affect Scales (PANAS) Negative Affect
Zeitfenster: Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
The Positive and Negative Affect Scales are brief screening measures that assess both positive and negative emotional experiences. This scale will allow for separate assessment of impact on negative mood.
Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
Change in Fatigue Severity Scale (FSS) across a three-week intervention
Zeitfenster: Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
Fatigue Severity Scale (FSS) is a well-validated 9-item clinical measure that assesses overall levels of mental and physical fatigue, with answers ranging from 1- "Strongly Disagree" to 7-"Strongly Agree".
Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
Change in Profile of Mood States (POMS) across a three week intervention
Zeitfenster: Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
The Profile of Mood States (POMS) is a psychological rating scale used to assess transient, distinct mood states. The POMS measures six different dimensions of mood swings over a period of time. These include: Tension or Anxiety, Anger or Hostility, Vigor or Activity, Fatigue or Inertia, Depression or Dejection, Confusion or Bewilderment. A total score will be evaluated in addition to the individual items.
Change from baseline (pre) to post three weeks of wearing the phototherapy device (Day 21).
Change in Wake After Sleep Onset (WASO) assessed using morning sleep diaries over the duration of the study
Zeitfenster: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
Wake after sleep onset (WASO), or the number of nocturnal awakenings, will be assessed using morning sleep diaries completed by the participant upon awakening. The mean WASO during the baseline period (pre) will be compared to after three weeks of wearing the phototherapy device (post).
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
Change in sleep efficiency assessed using morning sleep diaries over the duration of the study
Zeitfenster: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
Sleep efficiency, or the amount of time spent asleep during a sleep opportunity, will be assessed using morning sleep diaries completed by the participant upon awakening. The mean sleep efficiency during the baseline period (pre) will be compared to after three weeks of wearing the phototherapy device (post).
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
Change in total sleep time assessed using morning sleep diaries over the duration of the study
Zeitfenster: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
Total sleep time will be assessed using morning sleep diaries completed by the participant upon awakening. The mean total sleep time during the baseline period (pre) will be compared to after three weeks of wearing the phototherapy device (post).
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
Change in morning refreshed feeling assessed using morning sleep diaries over the duration of the study
Zeitfenster: Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.
Morning refreshed feeling will be assessed using morning sleep diaries completed by the participant upon awakening. The mean refreshed feeling during the baseline period (pre) will be compared to after three weeks of wearing the phototherapy device (post).
Change from mean baseline period (first two weeks of wear) to post three weeks of wearing the phototherapy device.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

University of Arizona

Mitarbeiter

CeraZ LLC

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

2. September 2021

Primärer Abschluss (Voraussichtlich)

30. Januar 2022

Studienabschluss (Voraussichtlich)

30. Januar 2022

Studienanmeldedaten

Zuerst eingereicht

1. November 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

1. November 2021

Zuerst gepostet (Tatsächlich)

11. November 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

11. November 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

1. November 2021

Zuletzt verifiziert

1. November 2021

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 2012256803

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Schlafen

  • Elsan
    European Clinical Trial Experts Network; Polyclinique Poitiers
    Abgeschlossen
    Machbarkeitsstudie zur Schlafendoskopie unter Hypnose in einem Schlafzentrum (DISE)
    Obstruktives Schlafapnoe-Syndrom | Hypnose | Drug Induce Sleep Endoscopy
    Frankreich
  • Brigham and Women's Hospital
    Charite University, Berlin, Germany; Stanford University
    Rekrutierung
    Biomarker für das zirkadiane Timing bei gesunden Erwachsenen
    Schlafstörungen, intrinsisch | Schlaf-Wach-Störungen | Schlafstörungen, zirkadianer Rhythmus | Fortgeschrittenes Schlafphasensyndrom (ASPS) | Verzögertes Schlafphasensyndrom | Schichtarbeits-Schlafstörung | Verzögerte Schlafphase | Nicht-24-Stunden-Schlaf-Wach-Störung | Fortgeschrittenes Schlafphasensyndrom und andere Bedingungen
    Vereinigte Staaten

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Sri Lanka

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren